Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

73.69
-0.3300-0.45%
Post-market: 73.690.00000.00%19:57 EDT
Volume:747.95K
Turnover:54.83M
Market Cap:2.52B
PE:-11.39
High:74.40
Open:73.01
Low:70.93
Close:74.02
52wk High:109.00
52wk Low:26.45
Shares:34.14M
Float Shares:28.53M
Volume Ratio:1.23
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.79
PE(LYR):-7.58

Loading ...

Nektar Therapeutics Q4 Swings to Loss, Revenue Declines

MT Newswires Live
·
Mar 13

Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss

MT Newswires Live
·
Mar 13

Stock Track | Nektar Therapeutics Plummets 5.07% Intraday Following Securities Class Action Lawsuit

Stock Track
·
Mar 13

Pomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures

Reuters
·
Mar 12

Will REZOLVE-AA Class Actions Over Trial Disclosures Change Nektar Therapeutics' (NKTR) REZPEG Narrative?

Simply Wall St.
·
Mar 10

BRIEF-Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 07

Nektar Therapeutics Reports 2025 Inducement Plan Stock Option Grants

Reuters
·
Mar 07

Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 65.16%, and institutional views are bullish

Earnings Agent
·
Mar 05

Nektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata

Reuters
·
Mar 04

BTIG Keeps Their Buy Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
Mar 02

Nektar Therapeutics Schedules Fourth-Quarter and Full-Year Financial Results Call

Reuters
·
Feb 27

Nektar Therapeutics to Present at TD Cowen Annual Health Care Conference

Reuters
·
Feb 25

A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration

Simply Wall St.
·
Feb 23

B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating

MT Newswires Live
·
Feb 23